In a move that signals the accelerating convergence of consumer electronics and preventive healthcare, Huawei has unveiled its latest smartwatch with a feature that could fundamentally alter how millions of people manage one of the world’s most pervasive chronic diseases. The Huawei Watch GT 6 Pro, announced alongside its sibling the Watch GT 6, introduces a diabetes risk assessment capability that the Chinese technology giant says can flag early warning signs of Type 2 diabetes — all from the wearer’s wrist.
The announcement, made during Huawei’s summer product launch event, positions the company at the vanguard of a rapidly expanding market for health-focused wearables. While competitors like Apple, Samsung, and Google have been layering health monitoring features into their smartwatch lineups for years, Huawei’s direct targeting of diabetes risk represents a notable escalation in ambition — and in the regulatory and scientific scrutiny that such claims inevitably invite.
A New Frontier in Wearable Health Monitoring
According to reporting by TechRepublic, the Huawei Watch GT 6 Pro leverages an advanced sensor array and proprietary algorithms developed through Huawei’s TruSense system to assess a user’s risk of developing Type 2 diabetes. The feature does not diagnose diabetes outright — an important distinction — but rather provides a risk score based on continuous monitoring of physiological signals including heart rate variability, blood oxygen saturation, sleep patterns, and other biometric data points collected over time.
Huawei has stated that the diabetes risk assessment feature was developed in collaboration with medical research institutions and has undergone clinical validation studies. The company claims the system can identify individuals at elevated risk with meaningful accuracy, potentially prompting users to seek formal medical evaluation before the disease progresses to a more advanced stage. This is particularly significant given that the International Diabetes Federation estimates that approximately 240 million adults worldwide are living with undiagnosed diabetes, and hundreds of millions more are in a pre-diabetic state without knowing it.
The Hardware Behind the Health Claims
The Watch GT 6 Pro itself represents a meaningful hardware upgrade over its predecessors. The device features a 1.43-inch AMOLED display, Huawei’s latest Kirin chipset optimized for wearable applications, and an expanded suite of sensors that Huawei collectively brands as TruSense. This sensor package includes an upgraded optical heart rate monitor, a SpO2 sensor, a skin temperature sensor, and an accelerometer — all working in concert to feed data into the watch’s on-device health analytics engine.
Battery life, long a competitive advantage for Huawei’s GT series over rivals running Wear OS or watchOS, remains robust. Huawei claims up to 14 days of typical use on a single charge for the GT 6 Pro, a figure that dwarfs the one-to-two-day battery life common among Apple Watch and Samsung Galaxy Watch models. This extended battery life is not merely a convenience feature in the health monitoring context — it enables the kind of continuous, multi-day data collection that underpins the accuracy of features like diabetes risk assessment and sleep analysis.
Why Diabetes Detection Matters at Scale
The global diabetes crisis is staggering in scope. According to the World Health Organization, approximately 422 million people worldwide have diabetes, and the disease is directly responsible for an estimated 1.5 million deaths annually. Type 2 diabetes, which accounts for roughly 90% of all cases, is closely linked to lifestyle factors including diet, physical activity levels, and obesity — precisely the kinds of variables that wearable devices are increasingly capable of tracking.
Early detection is widely regarded by endocrinologists and public health experts as one of the most effective interventions for reducing the long-term burden of Type 2 diabetes. When caught in the pre-diabetic phase, lifestyle modifications alone — increased physical activity, dietary changes, and weight management — can prevent or significantly delay the onset of full-blown diabetes in many patients. The potential for a consumer device worn by millions to serve as an early warning system is, in the estimation of many health technology analysts, genuinely transformative.
Regulatory and Scientific Questions Loom Large
However, the introduction of such features is not without significant caveats. As TechRepublic noted in its coverage, the diabetes risk feature is not a medical device in the regulatory sense. It has not received clearance from the U.S. Food and Drug Administration or equivalent bodies in most markets as a diagnostic tool. Huawei has been careful to frame the feature as a “risk assessment” rather than a diagnostic, a distinction that carries both legal and practical weight.
This semantic precision matters enormously. In the United States, any device that claims to diagnose a medical condition must undergo rigorous FDA review, a process that can take years and cost millions of dollars. By positioning the feature as a wellness tool rather than a diagnostic instrument, Huawei sidesteps the most onerous regulatory requirements — but also limits the clinical claims it can make. Users are advised to consult healthcare professionals if the watch flags elevated risk, a recommendation that underscores the feature’s role as a screening tool rather than a replacement for laboratory blood glucose testing.
The Competitive Race for Health Wearables Intensifies
Huawei’s move comes amid intensifying competition in the health wearable sector. Apple has been widely reported to be developing non-invasive blood glucose monitoring technology for future Apple Watch models, a project that has been in development for over a decade. Samsung, meanwhile, has been expanding the health capabilities of its Galaxy Watch line, including FDA-cleared electrocardiogram and blood pressure monitoring features in select markets. Google’s Fitbit division has also been investing heavily in health research partnerships.
Yet Huawei’s willingness to ship a diabetes-related feature now — rather than waiting for the kind of comprehensive regulatory approval that Apple has historically pursued — reflects a different strategic calculus. In markets across Asia, the Middle East, Africa, and parts of Europe where Huawei’s wearable market share is strongest, the regulatory environment for wellness-oriented health features is often less restrictive than in the United States. This gives Huawei a first-mover advantage in deploying features that competitors may be developing but have not yet brought to market.
Huawei’s Broader Health Ecosystem Ambitions
The diabetes risk feature does not exist in isolation. Huawei has been systematically building out a health and fitness ecosystem that spans hardware, software, and cloud services. The Huawei Health app, which serves as the companion platform for all Huawei wearables, aggregates data from the Watch GT 6 Pro and other devices to provide users with longitudinal health insights. Features include detailed sleep analysis with sleep apnea risk detection, stress monitoring, menstrual cycle tracking, and comprehensive fitness tracking across more than 100 workout modes.
Huawei has also signaled its intent to deepen partnerships with healthcare providers and researchers. The company’s health division has published multiple peer-reviewed studies on the accuracy of its wearable health monitoring technologies, and it has established research collaborations with hospitals and universities in China and Europe. These partnerships serve a dual purpose: they lend scientific credibility to Huawei’s health claims and generate the clinical data necessary to pursue regulatory approvals in markets where they may be required in the future.
Privacy Concerns and Geopolitical Headwinds
No discussion of Huawei’s consumer technology ambitions can avoid the geopolitical context in which the company operates. Huawei remains effectively banned from the U.S. market for most of its products, including smartphones and smartwatches, due to national security concerns raised by the U.S. government. The company’s wearables are not widely available through official channels in the United States, which limits the addressable market for the Watch GT 6 Pro in the world’s largest consumer electronics market.
Privacy considerations are also front and center. Health data is among the most sensitive categories of personal information, and the collection of biometric data by a Chinese technology company is likely to draw scrutiny from regulators and privacy advocates in multiple jurisdictions. Huawei has stated that health data collected by its devices is processed on-device where possible and that data stored in the cloud is encrypted and subject to strict access controls. Whether these assurances will satisfy regulators in Europe, where the General Data Protection Regulation imposes stringent requirements on health data processing, remains to be seen.
What This Means for the Future of Preventive Health
The Huawei Watch GT 6 Pro’s diabetes risk assessment feature, whatever its limitations, represents a meaningful step in the ongoing migration of health screening from clinical settings to consumer devices. The vision of a world in which a wristwatch can alert its wearer to emerging health risks — prompting early intervention that could prevent serious illness — is no longer speculative. It is arriving in increments, feature by feature, device by device.
For the hundreds of millions of people at risk of undiagnosed Type 2 diabetes, the promise is tantalizing: a device that costs a few hundred dollars and is worn daily could serve as a persistent, passive health sentinel. The challenge, as always, lies in ensuring that the technology is accurate enough to be useful, that its limitations are clearly communicated, and that the data it generates is handled with the care that health information demands. Huawei’s latest offering advances the conversation — but the most consequential chapters in this story are still being written.